We recently published a list of Top 20 Falling Stocks with Unusual Volume. In this article, we are going to take a look at ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk is set to benefit from a $150B market by 2030, with strong earnings potential and a favorable 14x forward P/E.

Eli Lilly's robust sales for Mounjaro and Zepbound along with its positive outlook for 2025 also work in its favor. Click ...

The scale of President Donald Trump’s tariffs has exceeded even the most bearish forecasts — and could impact these five ...

Norlys TV customers will see their monthly bills rise by up to 20 DKK starting July 1st. According to the company, this ...

- 08:15 (EU) ECB Interest Rate Decision: Expected to cut Key Rates by 25bps; Expected to cut Deposit Rate by 25bps to 2.25%; ...

Like Novo Nordisk's already-approved GLP-1 agonist Wegovy ... only reduce weight but also curb appetite. There was one red flag in the phase 2 data, as around a quarter of patients taking the ...

Novo Nordisk now has an Ozempic pill. Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NYSE: NVO), ...

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.